Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT112 with or without Cemiplimab in Prostate Cancer (PRO-MERIT)
NCT04382898Phase 2Terminated
- Sponsor
- BioNTech SE
- Start
- Dec 2019
- Primary completion
- Jan 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 4
01
Overview
A Phase 2 trial of BNT112 in prostate cancer (PCa), sponsored by BioNTech SE. Started Dec 2019; status: terminated.
02
Drugs
BNT112
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04382898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04382898.